Iain McInnes - Publications#

>400 peer reviewed papers current searchable on pubmed; h-index 111 (Google Scholar); >60,000 citations. Clarivate Global Highly Cited Researcher based on multiple papers ranking in the top 1% by citations for field and year of publication. Exemplars below depict global leadership in clinical trials (in turn supporting approval of new therapies in the arthritis field particularly), in pathogenesis discovery and in hypothesis setting.

Selected Publications#

1. McInnes IB, Anderson JK et al Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis New Eng J Med, April 2021 in press

2. Alivernini S et al McInnes IB, Otto T, Kurowska-Stolarska M. Distinct tissue macrophage subsets regulate inflammation and provide a novel cellular and molecular mechanism for disease remission in rheumatoid arthritis. Nature Medicine 2020; 26, 1295–1306

3. McInnes IB, Behrens F, Mease PJ, Kavanaugh A, Ritchlin C, Nash P, Masmitja JG, Goupille P, Korotaeva T, Gottlieb AB, Martin R, Ding K, Pellet P, Mpofu S, Pricop L; EXCEED Study Group. Secukinumab Versus Adalimumab for Treatment of Active Psoriatic Arthritis (EXCEED): A Double-Blind, Parallel-Group, Randomised, Active-Controlled, Phase 3b Trial. Lancet. 2020; 395(10235):1496-1505.

4. Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB Guselkumab in Biologic-Naive Patients With Active Psoriatic Arthritis (DISCOVER-2): A Double-Blind, Randomised, Placebo-Controlled Phase 3 Trial. Lancet. 2020;395(10230):1126-1136.

5. Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, Gottlieb AB, Assudani D, Bedford-Rice K, Coarse J, Ink B, McInnes IB. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet 2020;395(10222):427-440.

6. Kurowska-Stolarska M, et al McInnes IB. MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis. Nature Commun. 2017;8:15877.

7. Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183-196.

8. Porter D, et al McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016;388(10041):239-47.

9. Mease PJ, McInnes IB, et al Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Eng J Med. 2015; 373 (14): 1329-39

10. McInnes IB, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137-46.